

Richard J Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12008062/publications.pdf>

Version: 2024-02-01

44
papers

7,138
citations

147801

31
h-index

243625

44
g-index

44
all docs

44
docs citations

44
times ranked

9178
citing authors

#	ARTICLE	IF	CITATIONS
1	Charting a Path Towards Asian American Cancer Health Equity: A Way Forward. <i>Journal of the National Cancer Institute</i> , 2022, 114, 792-799.	6.3	9
2	Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level. <i>Oncogene</i> , 2021, 40, 46-54.	5.9	8
3	Disparities in Cancer Care and the Asian American Population. <i>Oncologist</i> , 2021, 26, 453-460.	3.7	59
4	Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing. <i>Oncogene</i> , 2020, 39, 5734-5742.	5.9	17
5	Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. <i>Prostate</i> , 2020, 80, 1233-1243.	2.3	9
6	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	1.9	105
7	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 288-303.	9.4	107
8	Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. <i>Oncotarget</i> , 2018, 9, 2193-2207.	1.8	16
9	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017, 71, 952-960.	1.9	253
10	Expression of β -globin by cancer cells promotes cell survival during blood-borne dissemination. <i>Nature Communications</i> , 2017, 8, 14344.	12.8	96
11	Branched Chain RNA <i>In Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 363-369.	7.0	23
12	Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1028-1036.	0.8	122
13	Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 490-501.	1.6	11
14	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science</i> , 2015, 349, 1351-1356.	12.6	614
15	Cabozantinib and Prostate Cancer: Inhibiting Seed and Disrupting Soil?. <i>Clinical Cancer Research</i> , 2014, 20, 525-527.	7.0	10
16	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 501-508.	1.6	31
17	Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 440-446.	1.9	29
18	Circulating tumour cells monitoring treatment response in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 401-412.	27.6	110

#	ARTICLE	IF	CITATIONS
19	Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.. Oncotarget, 2014, 5, 1683-1698.	1.8	59
20	The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget, 2014, 5, 10678-10691.	1.8	36
21	Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 90-98.	2.0	32
22	Inertial Focusing for Tumor Antigen-Dependent and -Independent Sorting of Rare Circulating Tumor Cells. Science Translational Medicine, 2013, 5, 179ra47.	12.4	910
23	A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases. Clinical Cancer Research, 2013, 19, 3088-3094.	7.0	69
24	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer. Cancer Discovery, 2012, 2, 995-1003.	9.4	257
25	Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 3705-3714.	1.6	70
26	Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer. Clinical Genitourinary Cancer, 2010, 8, 29-36.	1.9	18
27	Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer. Science Translational Medicine, 2010, 2, 25ra23.	12.4	474
28	Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2010, 183, 2200-2205.	0.4	51
29	Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18392-18397.	7.1	1,454
30	Nerve Growth Factor Regulation of Cyclin D1 in PC12 Cells through a p21 ^{RAS} Extracellular Signal-regulated Kinase Pathway Requires Cooperative Interactions between Sp1 and Nuclear Factor- κ B. Molecular Biology of the Cell, 2008, 19, 2566-2578.	2.1	44
31	p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/ β -Catenin Signaling. Cancer Research, 2006, 66, 8529-8541.	0.9	39
32	ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochemical Pharmacology, 2002, 64, 827-836.	4.4	33
33	Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. Molecular and Cellular Biology, 2000, 20, 672-683.	2.3	342
34	Integration of Rac-dependent Regulation of Cyclin D1 Transcription through a Nuclear Factor- κ B-dependent Pathway. Journal of Biological Chemistry, 1999, 274, 25245-25249.	3.4	260
35	The Cyclins and Cyclin-Dependent Kinase Inhibitors in Hormonal Regulation of Proliferation and Differentiation*. Endocrine Reviews, 1999, 20, 501-534.	20.1	299
36	pp60v- Induction of Cyclin D1 Requires Collaborative Interactions between the Extracellular Signal-regulated Kinase, p38, and Jun Kinase Pathways. Journal of Biological Chemistry, 1999, 274, 7341-7350.	3.4	214

#	ARTICLE	IF	CITATIONS
37	Activation of the cyclin D1 Gene by the E1A-associated Protein p300 through AP-1 Inhibits Cellular Apoptosis. <i>Journal of Biological Chemistry</i> , 1999, 274, 34186-34195.	3.4	166
38	Cell cycle genes in chondrocyte proliferation and differentiation. <i>Matrix Biology</i> , 1999, 18, 109-120.	3.6	43
39	Transforming Potential of Dbl Family Proteins Correlates with Transcription from the Cyclin D1 Promoter but Not with Activation of Jun NH2-terminal Kinase, p38/Mpk2, Serum Response Factor, or c-Jun. <i>Journal of Biological Chemistry</i> , 1998, 273, 16739-16747.	3.4	84
40	Fos Family Members Induce Cell Cycle Entry by Activating Cyclin D1. <i>Molecular and Cellular Biology</i> , 1998, 18, 5609-5619.	2.3	221
41	Inhibition of Cyclin D1 Kinase Activity Is Associated with E2F-Mediated Inhibition of Cyclin D1 Promoter Activity through E2F and Sp1. <i>Molecular and Cellular Biology</i> , 1998, 18, 3212-3222.	2.3	152
42	The effect of tumor necrosis factor- α and cAMP on induction of AP-1 activity in MA-10 tumor leydig cells. <i>Endocrine</i> , 1997, 6, 317-324.	2.3	30
43	Reduced Cyclin D1 Expression in the Cerebella of Nutritionally Deprived Rats Correlates with Developmental Delay and Decreased Cellular DNA Synthesis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 1009-1020.	1.7	22
44	Angiotensin II Activation of Cyclin D1-dependent Kinase Activity. <i>Journal of Biological Chemistry</i> , 1996, 271, 22570-22577.	3.4	130